BioSpace News Archive

Apogenix announced that a new publication in Human Vaccines & Immunotherapeutics highlights the advantages of hexavalent CD40 agonists, such as HERA-CD40L, in the targeting of CD40 in immuno-oncology.

Firma Clinical Research, a niche service provider, is partnering with The Myositis Association on a multi-faceted project to better integrate the experience of patients into the training of clinical trial investigators and support providers.

According to a new study carried out at the University of Eastern Finland, the distribution of drug molecules within the brain can be improved by utilizing LAT1, which is expressed highly in the brain.

Artios Pharma Limited announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.

Penlon Ltd, UK-based manufacturer of Anaesthesia equipment, is proud to announce the launch of the new Sigma EVA, an advanced electronic vaporizer specifically designed to provide a better way to deliver of Desflurane.

Knopp’s lead Kv7 platform candidate advancing toward clinical studies in KCNQ2 epileptic encephalopathy

Interview focused on ZyVersa’s Innovative Drug Therapies in Development for Patients with Inflammatory and Renal Diseases

CytoSorbents Corporation, a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a new publication entitled, “Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study,” in the journal Critical Care.

BioLineRx Ltd. announced dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, multi-arm mechanism that targets patient-specific tumor neoantigens.

Citius Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 7,821,230 shares of its common stock and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock, priced at-the-market.